

Declaration of Edmund J. Elder, Jr., Ph.D., R.Ph.

In the United States Patent and Trademark Office

Before the Patent Trial and Appeal Board

AMERIGEN PHARMACEUTICALS LIMITED,

Petitioner,

v

SHIRE LLC,

Patent Owner.

U.S. Patent No. 8,846,100 to Shojaei et al.
Appln. No. 11/383,066, filed May 12, 2006
Issue Date: September 30, 2014

Title: CONTROLLED DOSE DRUG DELIVERY SYSTEM

Inter Partes Review No. Unassigned

Declaration of Edmund J. Elder, Jr., Ph.D., R.Ph.

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	SUMMARY OF EDUCATION, PROFESSIONAL EXPERIENCE, AND QUALIFICATIONS	1
II.	LEGAL PRINCIPLES	5
	A. Claim Construction.....	5
	B. Anticipation	5
	C. Obviousness.....	6
III.	THE '100 PATENT	7
	A. Patent bibliography.....	7
	B. The scope of my report with respect to the '100 patent.....	14
	C. The art that applies to the '100 patent is biopharmaceutics.....	15
	D. Description of the art during the relevant timeframe.....	17
	E. The disclosure of the '100 patent.	18
IV.	THE STATE OF THE ART	23
	A. Amphetamines and methylphenidate were the drugs used to treat ADHD.....	23
	B. Drug delivery systems are ways of controlling how a drug is released in the body.....	25
	C. The art of making repeat-action dosage forms to relieve a patient of the burden of taking multiple single-dosages in a day was decades old by 2006.....	26
	D. There is a long history of therapeutic use of mixed amphetamines, much of it for the treatment of attention deficit hyperactivity disorder (ADHD).....	30

E.	The widespread use of exterior coatings on dosage forms in the 1995-2005 time period.	31
1.	<i>The use of HPMC-based film coatings on the exterior was common from 1995 until the filing of the application that eventually became the '100 patent.....</i>	33
2.	<i>The use of modified film coatings to provide delayed pulsed release was common for decades prior to the filing of the application that eventually became the '100 patent.....</i>	33
V.	THE RELEVANT PATENTS AND PRINTED PUBLICATIONS.....	35
A.	U.S. Patent No. 6,322,819.....	35
B.	U.S. Patent No. 6,605,300.....	39
C.	Kratochvil.....	41
D.	Additional references demonstrate that amphetamines required dose-titration, which was well known by a person of ordinary skill. .	43
VI	HOW A PERSON OF ORDINARY SKILL IN THE ART WOULD READ THE WORDING OF THE CLAIMS IN VIEW OF THE DISCLOSURE OF THE '100 PATENT AND THE ASSERTED ART.	44
VII	ONE OF ORDINARY SKILL IN THE ART WOULD UNDERSTAND THE '819 PATENT TO DISCLOSE EACH AND EVERY ELEMENT OF THE '100 PATENT.	47
A.	The '819 patent discloses each limitation of claim 1 of the '100 patent.	47
1.	<i>“(a) an immediate release bead comprising at least one amphetamine salt;”</i>	48
2.	<i>“(b) a first delayed release bead comprising at least one amphetamine salt; and”</i>	50
3.	<i>“(c) a second delayed release bead comprising at least one amphetamine salt;”</i>	53

4.	<i>“wherein the first delayed release bead provides pulsed release of the at least one amphetamine salt and the second delayed release bead provides sustained release of the at least one amphetamine salt;”</i>	57
5.	<i>“wherein the second delayed release bead comprises at least one amphetamine salt layered onto or incorporated into a core; a delayed release coating layered onto the amphetamine core; and a sustained release coating layered onto the delayed release coating, wherein the sustained release coating is pH-independent;”</i>	64
6.	<i>“and wherein the first delayed release bead and the second delayed release bead comprise an enteric coating.”</i>	65
B.	The '819 patent discloses a pharmaceutical composition consisting of three beads.....	66
C.	The '819 patent discloses the limitations of dependent claims 2-4.	68
D.	The '819 patent discloses the pharmacokinetic parameters claimed in dependent Claims 5-12.....	71
E.	The '819 patent teaches every limitation of claims 13-21.....	77
F.	The '819 patent discloses claims 22-30.	82
G.	The '819 patent discloses claim 31.	86

VIII. ONE OF ORDINARY SKILL IN THE ART WOULD UNDERSTAND THAT ALL CLAIMS OF THE '100 PATENT ARE OBVIOUS IN LIGHT OF THE '300 PATENT, IN VIEW OF KRATOCHVIL.....88

A.	One skilled in the art would be motivated to combine Kratochvil with the '300 patent.	88
B.	The '300 patent, in view of Kratochvil, discloses each limitation of claim 1 of the '100 patent.....	92

1.	<i>“(a) an immediate release bead comprising at least one amphetamine salt;”</i>	93
2.	<i>“(b) a first delayed release bead comprising at least one amphetamine salt; and”</i>	95
3.	<i>“(c) a second delayed release bead comprising at least one amphetamine salt;”</i>	98
4.	<i>“wherein the first delayed release bead provides pulsed release of the at least one amphetamine salt and the second delayed release bead provides sustained release of the at least one amphetamine salt;”</i>	103
	a. “(1) the first delayed release bead [that] provides pulsed release of the at least one amphetamine salt” ...	103
	b. “(2) second delayed release bead [that] provides sustained release of the at least one amphetamine salt”	104
5.	<i>“wherein the second delayed release bead comprises at least one amphetamine salt layered onto or incorporated into a core; a delayed release coating layered onto the amphetamine core; and a sustained release coating layered onto the delayed release coating, wherein the sustained release coating is pH-independent;”</i>	107
6.	<i>and wherein the first delayed release bead and the second delayed release bead comprise an enteric coating.</i>	109
C.	The '300 patent discloses the enteric limitations of dependent Claims 2-4.	111
D.	The '300 patent, in view of Kratochvil, discloses the pharmacokinetic parameters claimed in dependent claims 5-12.	114
E.	The '300 patent teaches every limitation of claims 13-21 and claim 31.	121
F.	The '300 patent discloses every limitation of claims 22-30.	126

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.